Approvals
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
JT Gains World-First Topical JAK Inhibitor Approval
Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
J&J's Stelara Gets Europe OK For Pediatric Psoriasis
The European Commission has backed J&J's blockbuster to treat children with psoriasis but the drug has fallen foul of NICE for ulcerative colitis.
Horizon Sees Blockbuster Future For Tepezza After US Approval
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Novartis MS Drug Mayzent Gets Europe OK
Mayzent is the first oral treatment specifically indicated for patients with secondary-progressive multiple sclerosis and while it is expected to be a blockbuster, the company tells Scrip that educational programs for physicians are a priority.
Pipeline Watch: Phase III Starts With EB-101, Tavapadon, Ziresovir
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
Recordati's Isturisa Approved For Cushing's In EU
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
Pipeline Watch: Phase III Starts For Tideglusib, Infigratinib, Galinpepimut-S
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.